The human tumor clonogenic assay in the treatment of patients with lung cancer.
The human tumor clonogenic assay has allowed the growth of human tumor cells and their testing to chemotherapeutic agents in vitro in a manner much like bacterial antibiotic sensitivities. This report deals with the in vitro test results compared with the in vivo therapeutic sensitivities of human lung cancer. Three hundred twenty-six lung tumor specimens from either primary or metastatic disease were plated using a two-layer technique. Of these, 68% (223) were grown and 41% (133) were applicable to chemosensitivity testing. Only 28 patients were considered for a retrospective analysis of in vitro tumor sensitivity versus in vivo tumor response to chemotherapeutic agents. Among them the percentage of true positives for the assay was 60%, while the percentage of true negatives was 91%. This technique has been encouraging in its initial stages and, with further development, may have an expanding role in the treatment of patients with lung cancer.